[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer

NCT05903807RecruitingPHASE2INTERVENTIONAL

Summary

Key Facts

Lead Sponsor

Aalborg University Hospital

Enrollment

50

Start Date

2023-11-17

Completion Date

2026-12-01

Study Type

INTERVENTIONAL

Official Title

[68Ga]Ga-FAPI-46 PET/CT: the Diagnostic Accuracy for Primary Staging and Re-staging of Patients with Ovarian Cancer

Interventions

68Ga-FAPi-46

Conditions

Ovarian Cancer

Eligibility

Age Range

18 Years+

Sex

FEMALE

Inclusion Criteria:

* Newly diagnosed with biopsy verified ovarian cancer or highly suspected to have ovarian cancer (based on all data presented at the gynecological cancer MDT) and referred to primary staging with FDG PET/CT
* Deemed resectable and operable at the MDT with or without neoadjuvant chemotherapy
* Considered physically and mentally able to participate in the research project
* 18-years or older and able to consent to project participation
* Can read and understand Danish

Exclusion Criteria:

* Patients with non-resectable, inoperable, or recurrent ovarian cancer
* Patients with an imminent need for surgery or in an emergency
* Known concurrent other malignancy within the previous 5 years other than non-melanoma skin cancer
* Patients not suited for surgery or neoadjuvant chemotherapy followed by surgery
* Subject weighing more than 180 kg (weight limit scanner) or unable to fit within the imaging gantry
* History of allergic reactions / hypersensitivity attributed to 18F-FDG or 68Ga-FAPI-46.
* Severe claustrophobia unresponsive to oral anxiolytics
* Subjects with any medical condition or other circumstances that, in the opinion of the Investigator, would significantly decrease the reliability of data, achievement of study objectives or completing the study.
* Pregnant, lactating, or breastfeeding women.
* Potential pregnant women of childbearing potential \[1\] not using effective contraceptives \[2\]. Potential pregnancy will be ascertained by a pregnancy test (urine humane choriogonadotropin (HCG)) or serum b-HCG within 48 hours prior to the FAPI PET/CT.
* Inability to remain still for the duration of the examination

  1. Women of childbearing potential are defined as all women physiologically capable of becoming pregnant, i.e., not sterilized (bilateral tubectomy/occlusion, hysterectomy, bilateral oophorectomy) and not post-menopausal. In cases of uncertain menopausal status, serum follicle stimulating hormone (FSH) levels and menstruation history can be assessed
  2. Effective contraceptives include sexual abstinence, vasectomized partner, combined hormonal contraception (oral, intravaginal, transdermal), progesterone-only contraceptive (oral, injectable, implantable), or working intrauterine device (hormonal, non-hormonal).

Outcome Measures

Primary Outcomes

Diagnostic accuracy

Diagnostic accuracy Compare the FAPI PET/CT and FDG PET/CT findings in primary tumor, regional lymph nodes and distant metastases to a histopathological reference standard where the sensitivity, specificity, positive predicative value, and negative predicative values of the PET/CTs are determined, both at primary staging and at restaging

Time frame: 2 years

Staging

Compare the cancer stage as determined by FAPI PET/CT compared to conventional imaging (including FDG PET/CT) at primary staging and at restaging (after neoadjuvant chemotherapy). The proportion of patients downstaged, unchanged stage, and upstaged, due to the added FAPI PET/ CT are determined.

Time frame: 2 years

Patient management

Investigate what proportion of patients will be (hypothetically) treated differently due to an added FAPI PET/CT at primary staging and at restaging (after neoadjuvant chemotherapy) by the treating clinicians

Time frame: 2 - 2.5 years

Secondary Outcomes

Uptake values

Standardized uptake value (SUV) and tumor-to-background ratio (TBR) values for primary, regional lymph nodes, and distant metastases for FAPI PET/CT and compare these values to FDG PET/CT, both at primary staging and at restaging (after neoadjuvant chemotherapy)

Time frame: 2 years

Chemotherapy effect on uptake values

Changes in SUV and TBR in primary, regional lymph nodes, and distant metastases for FAPI PET/CT - from before to after neoadjuvant chemotherapy and compare these values to the FDG PET/CT parameters.

Time frame: 2 - 2.5 years

Unexpected 68Ga-FAPI-46 PET/CT findings

Seek supplementary information in medical records, biochemistry, pathology, or other imaging modalities for a final diagnosis/condition in cases of unexpected FAPI PET/CT findings not related to the known cancer

Time frame: 1-2 years

Interobserver readability

Conduct an interobserver study of FAPI PET/CTs performed in the present and other future FAPI PET/CT in cancers studies.

Time frame: 4 years

Prognostic value

Investigate the prognostic value of FAPI PET/CT versus FDG PET/CT by conducting a 10 years follow up on included cancer patients. Overall survival (OS) and Recurrence free survival (RFS) will be estimated

Time frame: 10 years

Locations

Aalborg University Hospital, Aalborg, Denmark

Linked Papers

2022-12-07

Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies

Background Currently, fluorine-18-fluorodeoxyglucose (18F-FDG) is the most frequently used diagnostical radiotracer for PET/computed tomography (PET/CT) in ovarian malignancies. However, 18F-FDG has some limitations. The fibroblast activation protein inhibitor (FAPI) previously demonstrated highly promising results in studies on various tumor entities and 68Ga-labeled FAPI presents a promising alternative to 18F-FDG. This study aimed to compare the performance of 68Ga-FAPI and 18F-FDG PET/CT for imaging of ovarian malignancies. Methods A total of 27 patients were included in this retrospective study conducted at the Affiliated Hospital of Southwest Medical University between June 2020 and February 2022. The 18F-FDG and 68Ga-FAPI uptakes of tumors, lymph nodes, and distant metastases were quantified using the maximum standardized uptake values, and the tumor-to-background ratios were also evaluated and calculated by using the Wilcoxon signed-rank test. Results Twenty-one patients with suspected (n = 11) and previously treated ovarian malignancies (n = 10) were in statistical analysis finally. For detecting tumors, 68Ga-FAPI PET/CT was more sensitive than 18F-FDG PET/CT [14 of 14 (100%) vs. 11 of 14 (78%)], lymph node metastases [75 of 75 (100%) vs. 60 of 75 (80%)] and superior to 18F-FDG PET/CT in terms of the peritoneal and pleural metastases [9 of 9 (100%) vs. 5 of 9 (56%)]. For four of the newly diagnosed patients (n = 11), 68Ga-FAPI PET/CT upstaged the clinical stage compared to 18F-FDG PET/CT. Conclusion 68Ga-FAPI PET/CT has superior potential in the detection of ovarian cancers, especially in peritoneal carcinomatosis. 68Ga-FAPI PET/CT may be a promising supplement for staging and follow-up of ovarian malignancies.

Linked Investigators